A series of unexplained pneumonia cases (with a history of work or residence around the Huanan seafood wholesale market) were admitted to a hospital in Wuhan, Hubei province, China. Their clinical presentations were similar to viral pneumonia and some patients rapidly developed life-threatening acute respiratory diseases (ARDS) \[[@B1]\]. A novel coronavirus was then identified by sequencing the whole genome of the virus isolated from the patients and was named COVID-19 by the WHO \[[@B2],[@B3]\]. To date, more than 80,000 confirmed cases have been identified in 34 provinces of China, more than 49,000 are from Wuhan city and the virus has been found in Japan, Thailand, South Korea, USA, etc \[[@B4],[@B5]\].

Generally, the majority of COVID-19-positive patients are present with general symptoms of respiratory infection with a case fatality rate of 1.4--4% \[[@B3],[@B6],[@B7]\]. In some cases that develop severe or critical illness, death may be due to massive alveolar damage and progressive respiratory failure, with a higher mortality rate (38--60%) \[[@B8],[@B9]\]. However, little is known regarding the clinical markers for the risk of nonsurvivors in patients with COVID-19.

The purpose of this study was to explore biomarkers for disease progression and the risk of nonsurvivors. We hope that our research will help clinicians identify patients with a high risk of nonsurvivors at an early stage.

Materials & methods {#S0001}
===================

Study design & participants {#S0002}
---------------------------

In this retrospective study, we included discharged patients, including deaths, hospitalized with COVID-19 pneumonia in the Central Hospital of Wuhan from 1 January to 20 February 2020. COVID-19 was defined as a positive result on real time reverse transcriptase PCR and 'ground-glass opacity' on computed tomography (CT). This study was approved by the Ethics Commission of the Central Hospital of Wuhan. Written informed consent was waived by the Ethics Commission of the designated hospital under the criteria of emerging infectious diseases. The classification of diseases used is as described previously \[[@B10],[@B11]\].

Participants' characteristics & data collection {#S0003}
-----------------------------------------------

This study retrospectively analyzed the patients' medical history, epidemiological data (including workplace), history of disease exposure, fever, cough, headache, diarrhea and chest pain, etc. The laboratory tests included liver function, kidney function, blood cell count, COVID-19 nucleic acid and tests for other respiratory viruses etc. Data regarding medical expenses, lung CT image, drugs prescribed and comorbidities were also analyzed \[[@B12]\].

Clinical outcomes {#S0004}
-----------------

This study focused on discharged patients. The two patient subtypes included rehabilitation discharges and death cases.

Statistical analysis {#S0005}
--------------------

All data were expressed as median interquartile range (IQR), or percentages (%). Categorical data were tested using Fisher's exact test or *x*^2^ test. Normal distribution data were tested by independent *t*-test, while non-normal distribution data were tested by nonparametric Mann--Whitney *U* test. A binary logistic regression analysis was used to assess the independent predictors for the risk of nonsurvivors. To predict the risk of nonsurvivors, a receiver operating characteristic curve was plotted to determine the cut-off point for albumin. The data were analyzed using SPSS 20.0. A two-sided α score \<0.05 was considered statistically significant.

Results {#S0006}
=======

In this retrospective study, we included 134 discharged patients, including deaths. Patient demographics, characteristics, outcomes and medical expenses are summarized in [Table 1](#T1){ref-type="table"}. The median age of all the patients was 61.00 years, 69 (51.49%) of the patients were \>60 years of age, 65 (48.51%) were \<60 years of age and 75 (55.97%) of them were males. A total of 83.58, 96.27 and 100.00% had no history of smoking, drinking or a history of exposure to the Huanan seafood market, respectively. A total of 15 (11.19%) of the patients with COVID-19 were medical staff. Some patients had comorbidities including cardiovascular disease (44.03%), endocrine disorder (diabetes) (25.37%), digestive disorder (14.93%), respiratory disease (8.21%), neurological disease (17.16%) and solid tumor (9.70%). The median hospital stays and medical expenses for all the patients were 13.00 days and 24,093.38 yuan, respectively. Forty two (31.34%) patients died due to COVID-19 pneumonia.

###### Demographics, characteristics, outcomes and medical expenses of patients with COVID-19.

  Characteristics                                  Patients                           p-value                                                                                                
  ------------------------------------------------ ---------------------------------- -------------------------------- ---------------------------------- ---------------------------------- -------
  **Age, median (IQR), years**                     61.00 (46.75--69.25)               50.00 (31.00--63.00)             59.50 (52.75--67.75)               67.00 (56.00--75.00)               0.000
  \<60 (%)                                         65 (48.51)                         31 (68.89)                       15 (50.00)                         19 (32.20)                         0.001
  ≧60 (%)                                          69 (51.49)                         14 (31.11)                       15 (50.00)                         40 (67.80)                          
  **Gender, (%)**                                                                                                                                                                             
   Females                                         59 (44.03)                         21 (46.67)                       15 (50.00)                         23 (38.98)                         0.557
   Males                                           75 (55.97)                         24 (53.33)                       15 (50.00)                         36 (61.02)                          
  **Smoking, (%)**                                                                                                                                                                            
   Yes                                             22 (16.42)                         8 (17.78)                        5 (16.67)                          9 (15.25)                          0.942
   No                                              112 (83.58)                        37 (82.22)                       25 (83.33)                         50 (84.75)                          
  **Drinking, (%)**                                                                                                                                                                           
   Yes                                             5 (3.73)                           3 (6.67)                         1 (3.33)                           1 (1.69)                           0.412
   No                                              129 (96.27)                        42 (93.33)                       29 (96.67)                         58 (98.31)                          
  **Exposure to Huanan seafood market, (%)**                                                                                                                                                 
   Yes                                             0 (0)                              0 (0)                            0 (0)                              0 (0)                              NA
   No                                              134 (100)                          45 (100.00)                      30 (100.00)                        59 (100.00)                         
  **Occupation, (%)**                                                                                                                                                                         
   Medical staff                                   15 (11.19)                         8 (17.78)                        5 (3.73)                           2 (3.39)                           0.039
   Nonmedical staff                                119 (88.81)                        37 (82.22)                       25 (83.33)                         57 (96.61)                          
  **Chronic disease, (%)**                                                                                                                                                                    
   Cardiovascular disease                          59 (44.03)                         12 (40.00)                       14 (46.67)                         33 (55.93)                         0.014
   Hypertension                                    44 (32.84)                         10 (33.33)                       11 (36.67)                         23 (38.98)                         0.173
   Endocrine disorder (diabetes)                   34 (25.37)                         6 (20.00)                        10 (33.33)                         18 (30.51)                         0.072
   Digestive disorder                              20 (14.93)                         5 (11.11)                        3 (9.99)                           12 (20.34)                         0.294
   Respiratory disease                             11 (8.21)                          2 (4.44)                         1 (3.33)                           8 (13.56)                          0.133
   Neurological disease                            23 (17.16)                         7 (15.56)                        5 (3.73)                           11 (18.64)                         0.915
   Solid tumor                                     13 (9.70)                          5 (11.11)                        3 (9.99)                           5 (8.47)                           0.902
  **Hospital stays, median (IQR), days**           13.00 (10.00--20.00)               14.00 (11.00--20.00)             15.50 (12.75--22.00)               11.00 (7.00--17.00)                0.009
  **Clinical outcomes, (%)**                                                                                                                                                                  
   Rehabilitation discharge                        92 (68.66)                         45 (100.00)                      30 (100.00)                        17 (28.81)                         0.000
   Died                                            42 (31.34)                         0 (0)                            0 (0)                              42 (71.19)                          
  **Medical expenses, median (IQR), yuan (RMB)**   24,093.38 (10,217.39--44,511.04)   13,588.28 (8825.39--30,426.43)   24,169.73 (11,221.73--34,855.10)   36,895.44 (12,726.83--61,336.93)   0.000

According to the severity of COVID-19 pneumonia ([Table 1](#T1){ref-type="table"}), the increase in the median age, percentage of patients ≥60 years, percentage of patients with cardiovascular disease, and the median medical expenses occurred concomitantly with the severity of COVID-19 pneumonia (all p-values \<0.05). However, the median hospital stay was the shortest in the critical group, as this may have been due to the quick disease progression and early patient death.

The clinical characteristics of the patients are summarized in [Table 2](#T2){ref-type="table"}. The most common symptoms were fever (84.33%), cough (76.87%), diarrhea (20.15%), muscle pain (19.40%), generally feeling sick and vomiting (11.19%), as well as 96.27% experiencing more than one symptom. Out of the 134 patients, 62 (46.27%) developed ARDS and 120 (89.55%) had bilateral pneumonia. Most were treated with oxygen (66.42%), antibiotics (97.76%), antiviral drugs (97.76%), hormones (66.42%) and immunoglobulin (59.70%). An increase in the percentage of patients with bilateral pneumonia and hormones used occurred concomitantly with an increase in the severity of COVID-19 pneumonia (all p \< 0.05).

###### Clinical characteristics and treatment strategies of patients with COVID-19.

  Characteristics                        Patients      p-value                                   
  -------------------------------------- ------------- ------------- ------------- ------------- -------
  **Clinical symptoms, (%)**                                                                      
   Fever                                 113 (84.33)   36 (80.00)    25 (83.33)    52 (88.14)    0.520
   Cough                                 103 (76.87)   32 (71.11)    21 (70.00)    50 (84.75)    0.158
   Stuffy nose                           2 (1.49)      0 (0)         1 (3.33)      1 (1.69)      0.499
   Runny nose                            2 (1.49)      0 (0)         1 (3.33)      1 (1.69)      0.499
   Sneeze                                0 (0)         0 (0)         0 (0)         0 (0)         NA
   Sore throat                           5 (3.73)      0 (0)         1 (3.33)      4 (6.78)      0.194
   Chest pain                            9 (6.72)      5 (11.11)     1 (3.33)      3 (5.08)      0.335
   Diarrhea                              27 (20.15)    6 (13.33)     10 (33.33)    11 (18.64)    0.099
   Headache                              8 (5.97)      3 (6.67)      1 (3.33)      4 (6.78)      0.787
   Muscle pain                           26 (19.40)    6 (13.33)     8 (26.67)     12 (20.34)    0.349
   Feel sick and vomit                   15 (11.19)    8 (17.78)     2 (6.66)      5 (8.47)      0.221
   More than one symptom                 129 (96.27)   41 (91.11)    29 (96.67)    59 (100.00)   0.060
  **Complications, (%)**                                                                          
   Acute kidney injury                   5 (3.73)      0 (0)         0 (0)         5 (8.47)      0.037
   Acute respiratory injury              4 (2.99)      0 (0)         0 (0)         4 (6.78)      0.073
   Septic shock                          2 (1.49)      0 (0)         0 (0)         2 (3.39)      0.275
   Ventilator-associated pneumonia       1 (0.75)      0 (0)         0 (0)         1 (1.69)      0.527
   Acute respiratory distress syndrome   56 (41.79)    0 (0)         5 (16.67)     51 (86.44)    0.000
  **Lung CT images, (%)**                                                                         
   Unilateral pneumonia                  13 (9.70)     10 (22.22)    2 (6.66)      1 (1.69)      0.002
   Bilateral pneumonia                   120 (89.55)   35 (77.78)    27 (90.00)    58 (98.31)    0.003
   Ground-glass turbidity                117 (87.31)   41 (91.11)    27 (90.00)    49 (83.05)    0.417
  **Treatment strategies, (%)**                                                                   
   Oxygen therapy                        89 (66.42)    0 (0)         30 (100.00)   59 (100.00)   0.000
   Extracorporeal membrane oxygenation   1 (0.75)      0 (0)         0 (0)         1 (1.69)      0.527
   Antibiotics                           131 (97.76)   44 (97.78)    30 (100.00)   57 (96.61)    0.593
   Antiviral drugs                       131 (97.76)   45 (100.00)   30 (100.00)   56 (94.92)    0.142
   Antifungal drugs                      5 (3.73)      0 (0)         1 (3.33)      4 (6.78)      0.194
   Hormones                              89 (66.42)    23 (51.11)    18 (60.00)    48 (81.36)    0.004
   Immunoglobulin                        80 (59.70)    25 (55.55)    19 (63.33)    36 (61.02)    0.768
   Kidney replacement therapy            1 (0.75)      0 (0)         0 (0)         1 (1.69)      0.527
   Invasive mechanical ventilation       5 (3.73)      0 (0)         0 (0)         5 (8.47)      0.037
   Noninvasive mechanical ventilation    41 (30.60)    0 (0)         0 (0)         41 (69.49)    0.000

CT: Computed tomography.

The laboratory results of the patients with COVID-19 are summarized in [Table 3](#T3){ref-type="table"}. An increase in the severity of COVID-19 pneumonia was associated with higher median values of leukocytes (p \< 0.001), neutrophils (p \< 0.001), D-dimer (p = 0.005), aspartate aminotransferase (p = 0.010), serum urea (p = 0.009), lactate dehydrogenase (p \< 0.001), myoglobin (p = 0.026), glucose (p \< 0.001), procalcitonin (p = 0.022) and C-reactive protein (p \< 0.001), lower platelets count (p = 0.005), lower albumin (p \< 0.001) and lower sodium (p = 0.03). The lymphocyte counts were lower in the critical group (p = 0.046). Few patients had co-infections with other viruses, bacteria, etc. The positivity rate of the first test for viral nucleic acid was 33.58%. Furthermore, with an increase in the severity of COVID-19 pneumonia, the positivity rate of the first test for viral nucleic acid increased accordingly (p = 0.010).

###### Laboratory test results of patients with COVID-19.

  Characteristics                                     Patients                  p-value                                                                        
  --------------------------------------------------- ------------------------- ------------------------- ------------------------- -------------------------- -------
  **Blood biochemical parameters, median (IQR)**                                                                                                                
   Leukocytes (3.5--9.5) 10^9^/l                      5.42 (3.87--7.43)         4.70 (3.34--6.07)         4.78 (3.78--6.24)         6.94 (4.49--12.54)         0.000
   Neutrophils (1.8--6.3) 10^9^/l                     3.74 (2.57--6.17)         2.86 (1.83--4.13)         3.54 (2.12--4.63)         5.61 (3.32--10.92)         0.000
   Lymphocytes (1.1--3.2) 10^9^/l                     1.02 (0.64--1.35)         1.15 (0.91--1.74)         1.16 (0.93--1.34)         0.74 (0.49--1.12)          0.046
   Platelets (125--350) 10^9^/l                       167.50 (130.75--216.00)   193.50 (160.00--226.00)   165.00 (141.25--228.25)   147.50 (109.75--194.50)    0.005
   Hemoglobin (130--175 g/l)                          126.00 (116.75--141.00)   126.00 (121.00--139.25)   126.50 (116.75--140.50)   127.00 (110.75--142.25)    0.938
   Monocytes (0.1--0.6) 10^9^/l                       0.35 (0.25--0.47)         0.36 (0.27--0.44)         0.45 (0.29--0.53)         0.28 (0.21--0.46)          0.734
   Activated partial thromboplastin time (20--40) s   29.20 (25.40--32.15)      29.6 (26.05--31.50)       26.40 (24.50--30.20)      30.10 (26.50--34.00)       0.099
   Fibrinogen (2--4) g/l                              3.06 (2.53--3.69)         2.82 (2.28--3.25)         3.13 (2.52--3.74)         3.34 (2.67--3.91)          0.128
   Prothrombin time (9--13) s                         11.80 (11.15--12.70)      11.8 (11.15--12.45)       11.40 (10.60--12.10)      12.00 (11.40--13.15)       0.027
   International normalized ratio (0.7--1.3)          1.02 (0.96--1.10)         1.02 (0.96--1.08)         0.98 (0.92--1.05)         1.04 (0.99--1.16)          0.021
   D-dimer (0--1) μg/ml                               0.64 (0.31--1.46)         0.34 (0.17--0.78)         0.57 (0.33--0.88)         1.15 (0.50--5.56)          0.005
   Total cholesterol (\<5.18) mmol/l                  3.58 (3.00--4.50)         3.63 (3.01--4.17)         3.84 (3.14--5.10)         3.40 (2.93--3.94)          0.433
   Triglyceride (\<1.7) mmol/l                        1.06 (0.79--1.54)         1.02 (0.73--1.51)         1.11 (0.78--1.49)         1.11 (0.86--1.73)          0.343
   Total protein (65--85) g/l                         65.30 (62.70--71.20)      64.80 (63.1--71.2)        64.70 (61.23--71.30)      66.15 (62.15--70.95)       0.900
   Albumin (40--55) g/l                               38.10 (33.90--41.65)      39.90 (38.30--42.90)      37.00 (34.15--42.55)      34.40 (31.38--39.15)       0.000
   Alanine aminotransferase (9--50) U/l               31.10 (13.10--33.20)      21.10 (12.35--34.30)      16.95 (13.03--28.90)      23.70 (15.35--33.75)       0.331
   Aspartate aminotransferase (15--40) U/l            25.70 (18.40--36.80)      20.30 (17.48--27.5)       21.55 (16.65--34.00)      31.60 (24.80--45.15)       0.010
   Total bilirubin (2--20.4) μmol/l                   10.10 (7.10--15.40)       8.35 (6.63--11.60)        9.65 (7.70--15.43)        13.00 (7.75--17.60)        0.182
   Serum urea (1.7--8.3) mmol/l                       5.07 (3.70--6.71)         4.46 (3.44--5.45)         4.81 (3.47--6.60)         6.13 (4.25--9.46)          0.009
   Serum creatinine (57--111) μmol/l                  69.05 (56.25--84.23)      63.15 (55.33--79.78)      68.50 (53.85--80.35)      73.10 (58.68--100.58)      0.282
   Alkaline phosphatase (40--150) U/l                 50.50 (40.75--60.50)      49.00 (41.00--58.00)      50.00 (39.00--56.00)      52.00 (40.75--67.50)       0.570
   Sodium ion (137--147) mmol/l                       141.05 (137.93--143.28)   142.75 (140.95--143.93)   140.60 (138.70--142.55)   139.90 (136.15--142.38)    0.003
   Potassium ion (3.5--5.3) mmol/l                    4.14 (3.85--4.46)         4.17 (3.98--4.43)         4.19 (3.72--4.49)         4.12 (3.80--4.49)          0.999
   Calcium ion (2.2--2.7) mmol/l                      2.19 (2.03--2.35)         2.21 (2.09--2.41)         2.24 (2.05--2.49)         2.13 (2.01--2.27)          0.363
   pH value (7.35--7.45)                              7.45 (7.42--7.47)         7.43 (7.39--7.47)         7.46 (7.43--7.47)         7.44 (7.42--7.46)          0.265
   Partial pressure of carbon dioxide (35--45 mmHg)   35.00 (31.00--39.00)      36.00 (32.00--40.00)      36.00 (31.00--38.00)      34.00 (29.50--38.00)       0.440
   Partial pressure of oxygen (80--100 mmHg)          81.00 (58.00--105.00)     100.00 (76.00--109.00)    78.00 (62.00--105.00)     66.00 (51.00--102.00)      0.406
   Creatine kinase (38--174) U/l                      94.00 (57.00--161.00)     81.00 (47.00--117.50)     83.80 (56.50--151.50)     125.00 (63.50--239.30)     0.064
   Lactate dehydrogenase (80--285) U/l                212.00 (164.00--317.00)   168.00 (140.00--217.50)   191.00 (163.00--236.00)   296.00 (212.00--467.50)    0.000
   Angiotensin-converting enzyme (12--68) U/l         21.65 (17.03--24.88)      22.70 (17.20--25.58)      20.50 (16.50--23.00)      21.00 (17.05--24.35)       0.645
   Myoglobin (14.3--105.5) ng/ml                      36.30 (18.05--84.40)      17.55 (12.83--35.28)      36.30 (17.90--91.45)      56.85 (32.85--174.10)      0.026
   Troponin (\<0.03) μg/l                             0.01 (0.00--0.03)         0.003 (0.002--0.015)      0.006 (0.002--0.030)      0.02 (0.009--0.066)        0.058
   Glucose (3.9--6.1) mmol/l                          5.90 (4.95--8.38)         4.95 (4.36--6.39)         5.48 (5.06--7.86)         7.41 (5.78--11.03)         0.000
   Procalcitonin (\<0.04) ng/ml                       0.09 (0.05--0.25)         0.05 (0.04--0.08)         0.06 (0.05--0.11)         0.22 (0.10--0.52)          0.022
   Interleukin 6 (\<7) pg/ml                          25.52 (9.64--57.32)       7.70 (4.45--10.95)        25.88 (2.22--31.82)       26.88 (9.68--78.67)        0.633
   Erythrocyte sedimentation rate (0--15) mm/h        25.00 (15.25--52.00)      25.00 (12.00--40.50)      27.00 (16.00--62.50)      27.00 (17.00--53.00)       0.291
   Serum ferritin (21.8--274.7) ng/ml                 297.98 (190.98--876.80)   210.20 (80.70--339.70)    244.20 (190.99--876.80)   818.92 (297.98--1339.86)   0.483
   C-reactive protein (0--0.5) mg/dl                  2.69 (0.94--6.25)         0.98 (0.35--3.28)         2.47 (0.61--4.59)         4.86 (2.36--10.60)         0.000
  **Co-infection (negative), (%)**                                                                                                                              
   Other respiratory viruses                          2 (1.49)                  2 (4.44)                  0 (0)                     0 (0)                      0.134
   Bacteria                                           8 (5.97)                  4 (8.88)                  1 (3.33)                  3 (5.08)                   0.566
   Fungus                                             8 (5.97)                  2 (4.44)                  0 (0)                     6 (10.17)                  0.139
   Mycoplasma                                         4 (2.99)                  1 (2.22)                  2 (6.66)                  1 (1.69)                   0.400
   Chlamydia                                          3 (2.24)                  1 (2.22)                  2 (6.66)                  0 (0)                      0.133
  **Viral nucleic acid (negative), (%)**                                                                                                                        
  **Test for the first time**                                                                                                                                   
   Negative                                           89 (66.42)                34 (75.56)                24 (80.00)                31 (52.54)                 0.010
   Positive                                           45 (33.58)                11 (24.44)                6 (20.00)                 28 (47.46)                  

A 51-year-old female medical staff tested positive for COVID-19, possibly due to exposure in the hospital and she developed fever and cough that lasted for 3 days. Her chest CT ([Figure 1](#F1){ref-type="fig"}) showed little ground glass opacities below the right lung ([Figure 1](#F1){ref-type="fig"}A). On the 5th day of her admission ([Figure 1](#F1){ref-type="fig"}B), the area of ground glass opacities below the right lung increased. On the 15th ([Figure 1](#F1){ref-type="fig"}C) and 23rd ([Figure 1](#F1){ref-type="fig"}D) days after treatment, the ground glass opacities in the right lung gradually reduced and the lung inflammation slowly resolved. A 66-year-old man infected with COVID-19 due to a meal, presented with fever, cough and shortness of breath for 6 days. His chest CT showed multiple, ground-glass turbidity ([Figure 1](#F1){ref-type="fig"}E). On the 5th ([Figure 1](#F1){ref-type="fig"}F), 9th ([Figure 1](#F1){ref-type="fig"}G) and 20th ([Figure 1](#F1){ref-type="fig"}H) day of admission after active treatment, the ground glass opacities in the lungs gradually reduced and the clinical symptoms improved.

![Chest computed tomography images.\
**(A--D)** A 51-year-old female medical staff. Initially of mild severity, her condition worsened after admission and she finally recovered slowly. **(E--H)** A 66-year-old man. Initially severe, the patient's condition slowly improved.](figure1){#F1}

The patients in the critical group were divided into group 1 (dead) and group 2 (surviving). The parameters affecting disease progression (p \< 0.05) as in [Tables 1--](#T1){ref-type="table"} [3](#T3){ref-type="table"} were included in [Table 4](#T4){ref-type="table"} to further explore whether disease progression was closely related to the risk of nonsurvivors. The clinical and laboratory indicators, closely related to the severity of patients with COVID-19 are summarized in [Table 4](#T4){ref-type="table"}. In group 1 and group 2, the median ages were 70.00 and 55.00 years, respectively (p \< 0.001). More cases of cardiovascular disease (64.29 vs 35.29%; p = 0.042), ARDS (100.00 vs 52.94%; p \< 0.001) and higher median values of D-dimer (1.67 vs 0.49; p = 0.017), lactate dehydrogenase (337.50 vs 258.00; p = 0.026) and glucose (7.85 vs 7.05; p = 0.031), along with lower counts of platelets (median, 134.00 vs 182.00; p = 0.028) and albumin (median, 33.45 vs 39.20; p \< 0.001) were found in group 1, as compared with group 2.

###### Clinical and laboratory indicators closely related to the severity of patients with COVID-19.

  Characteristics                                  Critical                  p-value                                             
  ------------------------------------------------ ------------------------- ------------------------- ------------------------- -------
  **Age, median (IQR), years**                     67.00 (56.00--75.00)      55.00 (43.50--61.50)      70.00 (63.75--78.00)      0.000
   \<60 (%)                                        19 (32.20)                12 (70.59)                9 (21.43)                 0.000
   ≧60 (%)                                         40 (67.80)                5 (29.411)                33 (78.57)                 
  **Chronic disease, (%)**                                                                                                        
   Cardiovascular disease                          33 (55.93)                6 (35.29)                 27 (64.29)                0.042
  **Complications, (%)**                                                                                                          
   Acute kidney injury                             5 (8.48)                  0 (0)                     5 (11.90)                 0.308
   Acute respiratory distress syndrome             51 (86.44)                9 (52.94)                 42 (100.00)               0.000
  **Lung CT images, (%)**                                                                                                         
   Unilateral pneumonia                            1 (1.69)                  0 (0)                     1 (2.38)                  1.000
   Bilateral pneumonia                             58 (98.31)                17 (100.00)               41 (97.62)                1.000
  **Treatment strategies, (%)**                                                                                                   
   Oxygen therapy                                  59 (100.00)               17 (100.00)               42 (100.00)               1.000
   Hormones                                        48 (81.36)                12 (70.59)                36 (85.71)                0.293
   Invasive mechanical ventilation                 5 (8.47)                  2 (11.76)                 3 (7.14)                  0.620
   Noninvasive mechanical ventilation              41 (69.49)                14 (82.35)                27 (64.29)                0.222
  **Blood biochemical parameters, Median (IQR)**                                                                                  
   Leukocytes (3.5--9.5) 10^9^/l                   6.94 (4.49--12.54)        4.62 (3.63--11.43)        7.11 (5.38--12.54)        0.298
   Neutrophils (1.8--6.3) 10^9^/l                  5.61 (3.32--10.92)        3.37 (2.84--8.91)         6.18 (3.61--11.27)        0.240
   Lymphocytes (1.1--3.2) 10^9^/l                  0.74 (0.49--1.12)         0.95 (0.56--1.16)         0.68 (0.46--1.04)         0.801
   Platelets (125--350) 10^9^/l                    147.50 (109.75--194.50)   182.00 (119.50--268.50)   134.00 (105.00--186.00)   0.028
   Prothrombin time (9--13) s                      12.00 (11.38--13.08)      11.80 (11.40--12.25)      12.10 (11.35--13.30)      0.514
   International normalized ratio (0.7--1.3)       1.04 (0.98--1.16)         1.03 (0.98--1.07)         1.05 (0.98--1.18)         0.505
   D-dimer (0--1) μg/ml                            1.06 (0.40--5.54)         0.49 (0.18--0.93)         1.67 (0.66--6.61)         0.017
   Albumin (40--55) g/l                            34.40 (31.38--39.15)      39.20 (34.25--43.20)      33.45 (30.78--35.85)      0.000
   Aspartate aminotransferase (15--40) U/l         31.50 (24.58--45.03)      29.60 (22.55--57.60)      33.40 (25.68--45.28)      0.333
   Serum urea (1.7--8.3) mmol/l                    6.04 (4.20--9.16)         3.91 (2.90--6.90)         6.55 (4.88--10.39)        0.291
   Sodium ion (137--147) mmol/l                    139.90 (135.98--142.30)   137.50 (132.90--141.85)   139.90 (136.25--142.95)   0.968
   Lactate dehydrogenase (80--285) U/l             291.50 (211.25--458.75)   258.00 (198.00--361.50)   337.50 (213.75--509.50)   0.026
   Myoglobin (14.3--105.5) ng/ml                   0.00 (0.00--53.88)        0.00 (0.00--27.55)        78.75 (43.25--378.93)     0.051
   Glucose (3.9--6.1) mmol/l                       7.41 (5.78--11.03)        7.05 (5.15--10.10)        7.85 (6.30--13.10)        0.031
   Procalcitonin (\<0.04) ng/ml                    0.22 (0.10--0.52)         0.17 (0.09--0.36)         0.26 (0.10--0.57)         0.057
   C-reactive protein (0--0.5) mg/dl               3.91 (1.52--9.01)         2.21 (1.02--6.28)         6.11 (3.11--11.51)        0.141

Taking nonsurvivors as the dependent variable, the significant risk factors ([Table 4](#T4){ref-type="table"}) were analyzed using a binary logistic regression. Even after adjusting for age, cardiovascular disease and ARDS, plasma platelets and albumin levels were still associated with the risk of nonsurvivors in the critical group (all p \< 0.05; [Table 5](#T5){ref-type="table"}).

###### Risk factors for nonsurvivors in the critical group by binary logistic regression analysis.

   Characteristics                      Odds ratio   95% CI for odds ratio   p-value   Odds ratio[^†^](#T5TFN1){ref-type="table-fn"}   95% CI for odds ratio[^†^](#T5TFN1){ref-type="table-fn"}   p-value[^†^](#T5TFN1){ref-type="table-fn"}
  ------------------------------------- ------------ ----------------------- --------- ----------------------------------------------- ---------------------------------------------------------- --------------------------------------------
  Age                                   1.114        1.049--1.183            0.000     /                                               /                                                          /
  Cardiovascular disease                3.300        1.016--10.719           0.047     /                                               /                                                          /
  Acute respiratory distress syndrome   7.539E9      0.000                   0.999     /                                               /                                                          /
  Platelets                             0.998        0.978--0.997            0.012     0.980                                           0.963--0.996                                               0.018
  D-dimer                               1.112        0.951--1.301            0.185     1.718                                           0.411--7.183                                               0.458
  Albumin                               0.789        0.677--0.920            0.002     0.777                                           0.614--0.983                                               0.036
  Lactate dehydrogenase                 1.004        1.000--1.008            0.073     1.004                                           0.997--1.011                                               0.229
  Glucose                               1.176        0.977--1.417            0.087     1.102                                           0.855--1.419                                               0.453

Adjusted for age, cardiovascular disease and acute respiratory distress syndrome. Patients in the critical group were included in the analysis.

OR: Odds ratio.

A receiver operating characteristic curve analysis was performed to verify the diagnostic accuracy of the platelets and albumin levels for the risk of nonsurvivors in the critical group. The area under the curve for platelets and albumin were 0.67 (95% CI: 0.50--0.83; p \< 0.05) and 0.79 (95% CI: 0.64--0.93; p \< 0.001), respectively. The optimal cut-off points for platelet and albumin were 155.00 10^9^/l and 35.1 g/l, respectively. At this level, the Youden index was: 0.36 (platelet), 0.51 (albumin); sensitivity: 70.59% (platelet, 95% CI: 0.44--0.90), 76.47% (albumin, 95% CI: 0.50--0.93); specificity: 65.00% (platelet, 95% CI: 0.48--0.79), 73.81% (albumin, 95% CI: 0.58--0.85). The area under the curve for albumin was higher than that for platelets ([Figure 2](#F2){ref-type="fig"}). Therefore, albumin may be a better predictive marker (cut-off point: 35.1 g/l) for the risk of nonsurvivors in the critical group.

![Predictive factors for the risk of nonsurvivors in critical group.\
The AUC for platelet **(A)** and albumin **(B)** were 0.67 (95% CI: 0.50--0.83; p \< 0.05) and 0.79 (95% CI: 0.64--0.93; p \< 0.001), respectively.\
AUC: Area under the curve.](figure2){#F2}

Discussion {#S0007}
==========

In this study, we identified differences in clinical manifestations, laboratory tests, therapeutic interventions with severity and the risk of nonsurvivors in patients with confirmed COVID-19. We found that albumin may be an independent predictive marker (cut-off point: 35.1 g/l) for the risk of nonsurvivors in critically ill patients with confirmed COVID-19. Our findings highlight the clinical significance of focusing on the levels of albumin as a predictor of a high risk of nonsurvivors in critically ill patients with COVID-19.

Albumin is synthesized by the liver, which plays an important role in maintaining body nutrition and osmotic pressure \[[@B13]\]. A decrease in the levels of albumin is most likely due to liver damage and is likely to be caused by adverse drug reactions and systemic inflammation in critically ill patients with COVID-19. Although, several studies have reported that albumin may predict disease severity in patients with COVID-19 \[[@B14],[@B15]\], we found that in critically ill patients, if the albumin level was less than 35.1 g/l, the risk of nonsurvivors is higher (sensitivity: 76.47%, 95% CI: 0.50--0.93; specificity: 73.81%, 95% CI: 0.58--0.85). However, as hypoproteinemia is defined as blood albumin \<25 g/l \[[@B16]\], it will be too late to add albumin at this stage, as the risk of nonsurvivors would be greatly increased. Therefore, we recommend using drugs such as human albumin (that raise levels of albumin) to reduce risk of nonsurvivors, due to decreased levels of albumin (less than 35.1 g/l) in critically ill patients. This may also help clinicians identify patients with high risk of nonsurvivors at an early stage. Low levels of albumin also indicate that the patient's nutritional status is poor and the body's immunity is reduced. However, the host's immune response against RNA viral infection is often weakened due to nutritional deficiencies, which may be overlooked during clinical diagnosis and treatment. Therefore, we recommend verifying the nutritional status of patients with COVID-19 before giving general treatments.

Similar to previous studies \[[@B8],[@B10],[@B11]\], the elderly and male patients with cardiovascular disease had higher morbidity and mortality. Fever and cough were the main symptoms. Elevated levels of neutrophils, D-dimer, lactate dehydrogenase, procalcitonin, C-reactive protein and decreased lymphocyte count were found. However, the elevation of D-dimer was not shown the independent risk factor of a nonsurvivor. In the critical group, there was one case with myocardial infarction, two cases with pulmonary thromboembolism and five cases with ischemic stroke in a group of nonsurvivors, however, there was only one case with ischemic stroke in the group of survivors; after analysis, there was no statistical difference between survivors and nonsurvivors in these three diseases. The proportion of patients without fever with COVID-19 was higher than that found in severe acute respiratory syndrome (SARS) coronavirus (1%) and Middle East respiratory syndrome (MERS) coronavirus infection (2%) \[[@B17]\]. Therefore, if surveillance teams focus on fever detection, patients with COVID-19 may be missed.

The case fatality rate (31.34%) of this study was similar to that by Prof Yu (28.4%), but significantly higher than that from other studies (1.4, 3.2, 11 and 15%) \[[@B1],[@B3],[@B8]\]. In addition, mortality rate in the critically ill was as high as 71.19%, probably because of the difference in sample sizes and case inclusion criteria. This study focused on discharged patients (including rehabilitation discharge and death cases) and no inpatients were included. The patients studied were infected with the first-generation of the virus, but the virus might be more virulent now.

The median hospital stay in the critical group was 1.5 days longer than that in the moderate group. Recently, studies have found that four patients with COVID-19 who met criteria for the discharge requirements had positive real time reverse transcriptase PCR results after 5--13 days in China. This suggests that at a proportion of the recovered patients may still be virus carriers \[[@B18]\]. Therefore, we recommend that recovering patients from the severe and critical groups should have to extend the duration of their hospital stay, so that they can get better rehabilitation services in the hospital.

In this study, the positivity rate for the first test for viral nucleic acid was 33.58%, however, similar to previous studies, the positivity rate increased to 78.36% after multiple tests \[[@B19]\]. These viral nucleic acid test results were inconsistent with the patient's clinical symptoms and lung CT imaging. This may have been caused by irregular sampling, incorrect PCR amplification and interpretation as well as unstable kits. Therefore, rapidly optimizing the sampling site, ensuring quality of testing kits and standard operating procedure should be done urgently to provide the best infrastructure for the testing of COVID-19.

Previous studies have shown that SARS and Middle East respiratory syndrome coronavirus (MERS-CoV) infection increased the levels of serum proinflammatory cytokines \[[@B20],[@B21]\]. In this study, we noted that higher median values of leukocytes, neutrophils and C-reactive protein were associated with the increased severity of COVID-19 pneumonia, which suggests that a cytokine storm is associated with disease severity. In this study, most patients were prescribed corticosteroids to reduce the inflammatory-induced lung injury. However, previous studies have reported that administering corticosteroids in patients with SARS and MERS did not affect mortality \[[@B22],[@B23]\]. Therefore, we recommend low- and moderate-dose corticosteroids for critically ill COVID-19-positive patients. However, the efficacy and adverse reactions need to be further studied. Although immunoglobulins were used extensively for COVID-19, it should be noted that a third of all critically ill SARS patients developed venous thrombo-embolism including pulmonary embolism during the outbreak in Singapore in 2003 \[[@B24]\], due to an immunoglobulin-induced increase of viscosity in hypercoagulable states. Therefore, immunoglobulins should be used with caution in critically ill patients with significantly elevated D-dimer or decreased platelets to prevent nonsurvivors from pulmonary embolism.

Currently, there are no studies on the beneficial effects of antiviral drugs \[[@B10]\]. Arbidol, oseltamivir, lopinavir and ritonavir treatments are not effective. However, remdesivir is currently in Phase III clinical trials and its efficacy is unknown. At present, some traditional Chinese medicine decoctions were used clinically, as their main action is to improve lung function and enhance host immunity against COVID-19 infection \[[@B25]\].

There were some limitations in this study. First, some cases were incompletely recorded and laboratory testing indicators were not complete, which will cause some deviations. In addition, the sample size may not be large enough and some bias may have occurred. Also, we undoubtedly missed asymptomatic cases, so our study cohort may represent only the more serious COVID-19 cases. Finally, this is a single-center retrospective study, so these results need further confirmation with a multicentric study.

Conclusion {#S0008}
==========

Albumin levels decreased with the progression of the disease and could be used as an independent predictor (cut-off point: 35.1 g/l) of the risk of nonsurvivors in critically ill patients with COVID-19. This may help clinicians to identify high risk of nonsurvivors among critically ill patients at an early stage.

###### Summary points

Background {#S0009}
----------

-   Exploring biomarkers closely related to death is of great significance for reducing the mortality of critically ill patients with COVID-19.

Materials & methods {#S0010}
-------------------

-   Patients admitted to hospital due to COVID-19 pneumonia were collected and the clinical characteristics and clinical outcomes were analyzed.

Results {#S0011}
-------

-   The severity of COVID-19 pneumonia was positively correlated with the decrease in levels of platelets and albumin (all p \< 0.05). In the critical group, even after adjusting for age, cardiovascular disease and acute respiratory diseases, plasma levels of albumin were still significantly correlated with the risk of nonsurvivors (p \< 0.05).

Conclusion {#S0012}
----------

-   Levels of albumin could be used as an independent predictor of the risk of nonsurvivors in critically illness patients with COVID-19.
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